Statistics

Total Visits

Views
Consistent benefit survival with cabazitaxel (CBZ) in metastatic castration resistant prostate cancer (mCRPC) in Spain: Updated results83

Select a period of time:

Number of views in the range

Views
Consistent benefit survival with cabazitaxel (CBZ) in metastatic castration resistant prostate cancer (mCRPC) in Spain: Updated results44

Views

Views
June 20254
July 202526
August 20250
September 20253
October 20257
November 20252
December 20252
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States18
Brazil12
United Kingdom6
Argentina3
Egypt1
Guatemala1
Tunisia1
Turkey1
Venezuela1
 

Top cities views

Views
Anchorage1
Buenos Aires1
Caruaru1
Chebba1
Clifton1
Dallas1
Dunoon1
Duque de Caxias1
Formiga1
Fort Bragg1